Immunotherapy

In this video, James Stevenson, MD, a medical oncologist and hematologist at Cleveland Clinic, highlighted findings from the PIONeeR trial, which was presented at ESMO Virtual Congress 2020.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, described findings from the PIONeer study, which was developed through a public-private partnership in France.

The Society for Immunotherapy of Cancer issued a clinical practice guideline on the use of immunotherapy for the treatment of multiple myeloma.

Patients with immune checkpoint therapy-induced inflammatory arthritis report significant social, functional and emotional impacts, compared with cancer and other side effects, according to findings published in BMC Rheumatology.

Patrick Hwu, MD, has been appointed president and CEO of Moffitt Cancer Center.

Non-small cell lung cancer mortality decreased substantially among the general U.S. population between 2013 and 2016, according to results of a retrospective study published in The New England Journal of Medicine.

In this video, Roy S. Herbst, MD, PhD, Yale Cancer Center and Smilow Cancer Hospital, of this year’s International Lung Cancer Congress focused on immunotherapy.

Roy S. Herbst, MD, PhD, of Yale Cancer Center and Smilow Cancer Hospital, discussed lectures given by both the current president of the International Association for the Study of Lung Cancer, Tetsuya Mitsudomi, MD, and past president, Giorgio Scagliotti, MD, PhD.

First-line nivolumab plus ipilimumab significantly extended OS compared with platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma, according to results of an interim analysis of the CheckMate 743 trial.

Parker Institute for Cancer Immunotherapy appointed John Connolly, PhD, as its chief scientific officer.